Rocket Pharmaceuticals Inc (RCKT) Receives a Buy from William Blair


In a report released yesterday, Raju Prasad from William Blair maintained a Buy rating on Rocket Pharmaceuticals Inc (RCKT). The company’s shares closed yesterday at $18.56.

Prasad observed:

“We believe this last point is key and de-risks the program as it progresses the expected clinical trial for RP- L102 using a refined manufacturing “Process near term that is expected to enroll roughly 12 patients in the United States and EU. We believe the use of higher cell doses, transduction enhancers, and commercial-grade vectors in “Process B” will promote higher VCN (≥1) resulting in more clinically meaningful outcomes. Overall, we view the update as positive for the program.”

According to TipRanks.com, Prasad is a 5-star analyst with an average return of 23.8% and a 66.7% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Allogene Therapeutics Inc, and Logicbio Therapeutics Inc.

Currently, the analyst consensus on Rocket Pharmaceuticals Inc is a Strong Buy with an average price target of $39.

See today’s analyst top recommended stocks >>

The company has a one-year high of $25.96 and a one-year low of $10.75. Currently, Rocket Pharmaceuticals Inc has an average volume of 299.3K.

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RCKT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts